Prior notification of a concentration

(Case M.11074 – L-GAM / EPIC BPIFRANCE / BIOSE)

Candidate case for simplified procedure

(Text with EEA relevance)

(2023/C 126/05)

1. On 30 March 2023, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— L-GAM GP II S.à.r.l. ('L-GAM', Luxembourg),

— EPIC Bpifrance (France),

— Biose Industrie SAS ('Biose', France), controlled by Microbiota Anima Group SAS and Cathay Capital Private Equity SAS.

L-GAM and EPIC Bpifrance will acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Biose.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following:

— L-GAM is an investment company based in Luxembourg that makes long-term investments in small and medium-sized private companies in Europe,

— EPIC Bpifrance is a French State public industrial and commercial institution which promotes the development and financing of small and medium-sized companies for the account of the French State, focused on innovation and technology,

— Biose is a biotechnology company focused on the microbiome sector providing contract development manufacturing organisation services, mainly for live biotherapeutic products and probiotics.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 ([2]) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.11074 – L-GAM / EPIC BPIFRANCE / BIOSE

Observations can be sent to the Commission by email or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').
([2]) OJ C 366, 14.12.2013, p. 5.

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË